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Fit for high altitude: are hypoxic challenge
tests useful? 
Idoneità all’alta montagna: i test all’ipossia 
sono davvero utili?  
Heinrich Matthys
Medical Director emeritus, University Hospital Freiburg, Freiburg, Germany
ABSTRACT
Altitude travel results in acute variations of barometric pres-
sure, which induce different degrees of hypoxia, changing the
gas contents in body tissues and cavities. Non ventilated air
containing cavities may induce barotraumas of the lung
(pneumothorax), sinuses and middle ear, with pain, vertigo
and hearing loss. Commercial air planes keep their cabin pres-
sure at an equivalent altitude of about 2,500 m. This leads to
an increased respiratory drive which may also result in symp-
toms of emotional hyperventilation. In patients with pre-
existing respiratory pathology due to lung, cardiovascular,
pleural, thoracic neuromuscular or obesity-related diseases
(i.e. obstructive sleep apnea) an additional hypoxic stress
may induce respiratory pump and/or heart failure. Clinical
pre-altitude assessment must be disease-specific and it
includes spirometry, pulsoximetry, ECG, pulmonary and sys-
temic hypertension assessment. In patients with abnormal
values we need, in addition, measurements of hemoglobin,
pH, base excess, PaO2, and PaCO2 to evaluate whether O2- and
CO2-transport is sufficient.
Instead of the hypoxia altitude simulation test (HAST), which
is not without danger for patients with respiratory insuffi-
ciency, we prefer primarily a hyperoxic challenge. The supple-
mentation of normobaric O2 gives us information on the
acute reversibility of the arterial hypoxemia and the reduc-
tion of ventilation and pulmonary hypertension, as well as
about the efficiency of the additional O2-flow needed during
altitude exposure. For difficult judgements the performance
of the test in a hypobaric chamber with and without supple-
mental O2-breathing remains the gold standard. The increas-
ing numbers of drugs to treat acute pulmonary hypertension
due to altitude exposure (acetazolamide, dexamethasone,
nifedipine, sildenafil) or to other etiologies (anticoagulants,
prostanoids, phosphodiesterase-5-inhibitors, endothelin
receptor antagonists) including mechanical aids to reduce
periodical or insufficient ventilation during altitude exposure
(added dead space, continuous or bilevel positive airway pres-
sure, non-invasive ventilation) call for further randomized
controlled trials of combined applications.
Keywords: Altitude exposure, drug therapy, hypoxic and
hyperoxic challenge tests, mechanical aids for insufficient
ventilation, pulmonary hypertension. 
RIASSUNTO 
Portarsi in alta quota implica variazioni in acuto della pressio-
ne barometrica che comportano vari gradi di ipossia, modifi-
cazioni nel contenuto di gas nei tessuti corporei e nelle cavità.
L’aria non ventilata contenuta nelle cavità può indurre baro-
traumi del polmone (pneumotorace), dei seni paranasali e
dell’orecchio medio, con possibile dolore, vertigine e perdita
dell’udito. Gli aerei commerciali pressurizzano le loro cabine
ad un equivalente di circa 2.500 m di altitudine. Questo com-
porta un aumento del drive respiratorio che può giungere a
dare gli stessi sintomi dell’iperventilazione su base emotiva.
Nei pazienti con patologie respiratorie preesistenti, con ma-
lattie polmonari, cardiovascolari, pleuriche, neuromuscolari
toraciche o correlate all’obesità (es.: apnee ostruttive nel son-
no) lo stress ipossico supplementare può portare all’insuffi-
cienza respiratoria o cardiaca.
La valutazione clinica prima dell’esposizione alla quota deve
perciò essere specifica per la patologia ed includere spirome-
tria, pulsossimetria, ECG, valutazione della pressione arterio-
sa sistemica e polmonare. Nei pazienti con valori anormali si
rendono necessarie ulteriori valutazioni di emoglobina, pH,
eccesso di basi, PaO2, e PaCO2 per valutare se il trasporto di O2
e di CO2 sia sufficiente.
Piuttosto che il test di simulazione dell’ipossia da alta quota
(HAST), che non è privo di pericoli per i pazienti in insufficien-
za respiratoria, preferiamo in prima battuta un test iperossi-
co. Infatti il supplemento di O2 in normobaria ci fornisce le
informazioni sulla reversibilità acuta dell’ipossiemia arteriosa
e sulla riduzione di ventilazione e pressione arteriosa polmo-
nare, così come sull’efficienza del supplemento di O2 necessa-
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rio durante l’esposizione in alta quota. In caso di risultato in-
conclusivo la ripetizione del test con e senza O2 in camera
ipobarica rimane il gold standard.
Il crescente numero di farmaci per il trattamento dell’iperten-
sione polmonare acuta da alta quota (acetazolamide, desa-
metasone, nifedipina, sildenafil) e da altre eziologie (anticoa-
gulanti, prostanoidi, inibitori della fosfodiesterasi-5, antago-
nisti dei recettori per l’endotelina), compresi i supporti mec-
canici per ridurre la ventilazione a carattere periodico o insuf-
ficiente durante l’esposizione all’alta quota (spazio morto,
pressione positiva continua o bilevel, ventilazione non invasi-
va) richiedono decisamente un maggior numero di studi con-
trollati e randomizzati sulle loro azioni combinate. 
Parole chiave: Alta quota, farmacoterapia, ipertensione pol-
monare, test all’ipossia e all’iperossia, ventilatori polmonari.     
INTRODUCTION
Altitude exposure became an increasingly common
phenomenon during the 20th century due to the pop-
ularity of various sporting activities (skiing, moun-
taineering, trekking) and greater availability of trans-
port facilities (air planes, cars, trains, cable cars).
It is the purpose of this article to focus on the possi-
ble dangers during acute altitude exposure of nor-
mal subjects and patients suffering in particular
from respiratory disorders. To be able to advise on
health issues and the risk of possible accidents, the
physician should not only know the patient’s cur-
rent medical condition but also the duration and the
type of the intended altitude exposure with its spe-
cific hazards [1]. We distinguish illnesses due to
rapid barometric pressure changes according to
whether they occur under conditions of acute, sub-
acute or chronic altitude exposure and whether they
occur in normal subjects or patients with pre-exist-
ing lung and/or respiratory pump diseases (Figure 1).
ACUTE ALTITUDE-RELATED ILLNESSES
Acute altitude exposure
A sudden cabin pressure loss of commercial air
planes at altitudes above 5,000-6,000 m or a rapid
ascent to this altitude breathing air under ambient
pressure can lead to decompression illness similar
to that recognised in diving accidents. Acute hypox-
ic exposure (balloon rides) may induce signs of
emotional hyperventilation, problems to speak, to
calculate followed by dizziness, nausea and vomit-
ing, but also uncritical euphoria. This situation can
be simulated in hypobaric chambers to demonstrate
the danger of altitude hypoxia to pilots and to study
patients at risk with or without O2 breathing [2-5].
Acute mountain sickness (AMS)
AMS affects 10-40% of lowlanders ascending to
moderate altitudes above 2,500 m and 60% of sub-
jects who reach altitudes of 4,000-5,000 m within a
few hours. Physical fitness does not protect against
any high altitude related illnesses. The incidence of
FIGURE 1: REDUCTION OF O2- AND N2-PARTIAL PRESSURES IN INSPIRED AIR AT BTPS CONDITIONS (100% SATURATED
WATER VAPOUR PRESSURE DEPENDS ONLY ON TEMPERATURE) WITH INCREASING ALTITUDE EXPOSURE (DECREASING
BAROMETRIC PRESSURE)
Altitude diseases due to hypoxia can be compensated by O2-breathing and/or travelling in pressurized cabins.
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6 AMS depends on ascent rate, whether the journey is
made by climbing or travelling by plane (La Paz,
Bolivia airport is at 4,100 m), car or train (the
Chinese Tibet railway reaches 5,000 m).
The AMS-symptoms start generally 6-12 hours after
arrival at altitude with headaches (in mild to mod-
erate cases with good response to analgesics), loss
of appetite, nausea, vomiting, fatigue, insomnia and
weakness. The Lake Louise scoring system allows
the severity of AMS to be graded (see Table 1) [6].
The heel-to-toe walking test is an additional check
of objective neurological signs such as ataxia. Mild
to moderate AMS disappears within 1-2 days with
ongoing acclimatisation. The development of som-
nolence and cognitive defects are signs of high alti-
tude cerebral edema (HACE), which may result in
progressive unconsciousness, coma and death with-
in 1-3 days due to herniation of the brain. It requires
adequate treatment whenever possible by immedi-
ate descent to lower altitude. The rapid response of
symptoms (headache with no response to anal-
gesics, low grade fever, dizziness, ataxia, altered
consciousness, confusion, impaired mentation,
drowsiness, stupor, coma) to oxygen and steroids
are consistent with the patho-mechanism of a vaso-
genic edema [7].
High altitude pulmonary edema (HAPE)
HAPE develops at altitudes above 2,500 m. It is a
high-permeability pulmonary edema caused by ele-
vated pulmonary capillary pressures due to alveolar
hypoxia [8]. It may affect primarily only one lung.
The initial onset is usually at night and not related
to the frequently observed periodic breathing at al-
titude, which is a major cause of poor sleep quality.
This so-called Cheyne-Stokes breathing is common
in normal subjects at altitude and disappears, like
AMS, during the first three nights. Chronic periodic
breathing has also been observed above 4,500 m
lasting for weeks.
Recent studies showed that HAPE is more frequent
in subjects with patent foramen ovale (PFO) who
develop at altitude an increasing right to left shunt
due to the hypoxic pulmonary vasoconstriction. In
general the mean O2-saturation at normal baromet-
ric pressures is lower in subjects who developed
HAPE at altitude compared to HAPE-resistant
climbers. It is not clear whether closure of PFO pre-
vents HAPE in these patients.
The symptoms of HAPE are dry cough, decreased
exercise performance, dyspnea at rest, orthopnea,
cyanosis, tachypnea (> 25 breaths/min), tachycardia
(> 100 beats/min), low grade fever, crackles on pul-
monary auscultation and ultimately hemoptysis and
death.
Prevention of altitude related illness
A slow and gradual ascent with sufficient time and
a recreational sleep before ascent is the best strat -
egy for successful acclimatisation. Also the sleeping
altitude prior to higher exposures and the individual
susceptibility is important. To prevent altitude-relat-
ed sickness, not more than a 500 m increase of
sleeping altitude per day above 2,500 m is recom-
mended, albeit there is little evidence to support
this. For a safe ascent, the general recommendation
is: climb high, sleep low, avoid doing more physical
exercise than needed. If this is not possible for logis-
tic or other reasons a prophylactic pharmacological
treatment to prevent symptoms of AMS, periodic
breathing and non-recreational sleep is recom-
mended: acetazolamide (Diamox®) 125 mg the
evening before ascent above 2,500 m and later
twice daily for a stay of some days. Possible side ef-
fects are gastrointes tinal symptoms and paresthe-
sias. Dexamethasone 4 mg can be taken the
evening before ascent and later twice daily, espe-
cially in patients with a history of asthma and for
prevention of HACE and HAPE. In subjects with a
history of HAPE, 30-40 mg of slow release nifedip-
ine may be given in addition. Mountaineers with se-
vere sleep disordered breathing at altitude improve
their nocturnal sleep quality by using benzodi-
azepines and/or a fitted mask with a dead space of
500 ml [9].
Management of manifest high altitude diseases
Mild and moderate AMS: Rest, avoidance of exer-
tion, acclimatisation, analgesia, antiemetics, and
azetazolamide 250 mg twice daily until descent are
recommended. Treatment of periodic breathing and
sleep disturbances is also primarily with acetazo-
lamide which stabilizes nocturnal O2-saturation, re-
duces awakenings and hence improves sleep quali-
ty. In addition benzodiazepines taken before sleep-
ing (Tenazepam® 10 mg) result in a significant de-
crease of periodic breathing without reduction of
next-day reaction time, wakefulness, cognition and
AMS-symptoms. Immediate descent is generally not
indicated in mild forms of AMS.
Severe AMS and HACE: Immediate descent below
2,500 m is recommended. If available, O2 with or
without pressure bag should be administered. Drug
therapy consists of acetazolamide 125 mg twice
daily, or dexamethasone 8 mg and later 4 mg every
6 hours.
HAPE and/or HACE: O2 breathing in- or outside a
pressure bag, and 10-20 mg slow release nifedipine
and 8 mg dexamethsone every 6 hours are recom-
mended [10]. Against headaches and pulmonary hy-
pertension, sildenafil should be administered
(Revatio®, Viagra®) as a vasodilator [11]. Immediate
descent below 2,500 m is recommended whenever
possible. In all cases, dehydration is a risk and it is
important to ensure a careful control of fluid balance.
SUBACUTE AND CHRONIC MOUNTAIN SICKNESS
(CMS)
Some persons do not acclimatize to altitudes of
2,500-5,000 m. In these patients AMS-symptoms
and sleep disturbances due to periodic breathing
persist. Other subjects apparently well adapted to
these altitudes for many months or years develop
CMS, also called Monge’s disease, characterized by
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thromboembolic complications), hypoventilation,
fatigue, dyspnea, cyanosis, clubbing of the fingers
and leg edema with cor pulmonale. If the patient
descends to lower altitudes, preferably at sea level,
these symptoms disappear within months without
need for further treatment. It seems that increasing
the respiratory dead space by a fitted mask im-
proves disordered breathing and might improve ery-
throcytosis and pulmonary hypertension also in
CMS [12]. The Pickwickian-like syndrome is char-
acterized by a primary depression of breathing
without upper airway obstruction, such as in pa-
tients with obstructive sleep apnea syndrome
(OSAS). The diagnosis requires exclusion of other
causes of chronic respiratory insufficiency such as
chronic obstructive pulmonary disease (COPD),
obesity related hypoventilation or primary heart dis-
eases causing polycythemia. CMS was first de-
scribed in 1928 in mine workers living in the Andes
of south America at an altitude between 3,000 and
5,000 m. Chronic altitude exposure during preg-
nancy leads to a reduced birth-weight of the child.
Deliveries at altitudes above 2,500 m for non-resi-
dents (also in aircraft) have an increased risk of
neonatal death compared to non-hypoxic environ-
ments (early closure of ductus botalli and hypoxic
vasoconstriction of the placenta vessels). Children
exposed to high altitude have less periodic breath-
ing at night than adults.
ALTITUDE EXPOSURE WITH PRE-EXISTING
RESPIRATORY DISEASES
Diseases of the lung and/or respiratory pump affect
the O2 and CO2 transport which is further impaired
by altitude exposure. Prophylactic recommenda-
tions and measures require disease-specific evalua-
tion of these patients prior to high altitude travel.
The British Thoracic Society (BTS) recommenda-
tions give detailed advice for doctors dealing with
patients suffering from respiratory disorders who are
planning air travel. Two billion passengers currently
fly worldwide each year on commercial planes,
about 5% having problems [13,14].
Flying with no or partial compensation of the envi-
ronmental barometric pressures at cruising altitudes
should be known in advance as well as the intend-
ed and final altitude of the travel (landing place).
Previous episodes of complications (the need for
supplemental oxygen, pulmonary hypertension,
asthma attacks, emotional hyperventilation, throm-
bo-embolic and cardiac diseases), decompression
and recompression symptoms during altitude travel
(difficulties in ventilating the middle ear and the si-
nuses), previous pneumothorax, obstructive and re-
strictive ventilatory defects and other causes of res-
piratory impairment should be carefully evaluated
(lung function tests and pulse oximetry) during the
medical consultation.
The BTS-guidelines recommend the hypoxic alti-
tude simulation test (HAST) breathing 15% FiO2 un-
der normobaric conditions in patients with respira-
tory insufficiency, if they present at sea level with a
SaO2 below 92% (PaO2 67-73 mm Hg) and/or addi-
tional risk factors (hypercapnia, FEV1 < 50% pred,
cardiac disease), if a hypobaric chamber exposition
(the ideal test) is not possible, which gives also in-
formation on possible barotraumata. We prefer in
these patients to administer first supplemental O2
(primum nihil nocere) and to control the possibility
to reach normal values of blood gases under normo-
baric conditions (Figures 2 and 3), if necessary in
the sleep laboratory, to exclude critical hypoventila-
tion at higher O2-flows and the need for non inva-
sive ventilation. A one night supplemental O2 chal-
lenge test provides also more meaningful informa-
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FIGURE 3: THE SAME COPD PATIENT AS IN FIGURE 2
BREATHING 2 L/MIN SUPPLEMENTAL NASAL O2 AT NIGHT
Sleep quality and pulmonary hypertension are improved, arterial
hypoxemia is normalized with unchanged hypercapnia. This patient
could tolerate a 7 hour flight breathing 4 L/min nasal O2 at rest in
a commercial aircraft with a cabin pressure equivalent to an altitude



















FIGURE 2: POLYSOMNOGRAPHY OF A COPD PATIENT
BREATHING 2 L/MIN NASAL AIR AT NIGHT
The patient shows a poor sleep quality due to frequent awaken-
ings, and continuous hypercapnic (transcutaneous PCO2), hypoxic
(transcutaneous PO2) and pulmonary hypertension (mean pul-





























6 of hypoxic patients who intend to travel for extend-
ed periods by plane, car or train in hypoxic environ-
ments. It may be important to correct for anemia
(Hb), because the O2-content of the blood is more
informative for assessing O2 delivery to the tissues
than SaO2 and PaO2-values. ECG recordings breath-
ing supplemental nasal O2 (2 L/min) compared to
the night without shows in many COPD-patients al-
so a dramatic fall of hypoxia-induced ventricular
premature beats (Figure 4). 
Pneumothorax and other forms of “trapped air”
Air in the pleural cavity will expand during ascent
and cause tension pneumothorax if it cannot escape
through a chest tube, preferably equipped with a
one-way valve (Figure 5). Patients with residual
“trapped air” after thoracic surgery or incompletely
expanded lungs and captured air in pleural or other
closed air-containing spaces in the body should not
be exposed to rapid altitude changes.
Asthma
Exposure of patients to moderate altitude, (such as
in Davos, Switzerland or Denver, US) breathing dry
air without strenuous exercise tends to improve
asthmatic symptoms, probably because of the lower
allergen load. This is especially the case for house
dust mite sensitive subjects, because the house dust
mite cannot reproduce at altitude levels with low
humidity. Acute exposure to higher altitudes or
breathing cold air during exercise may trigger hy-
perventilation-induced or so-called exercise-in-
duced asthma. Longer stays at altitudes of more
than 4,000 m generally reduce the bronchial hyper-
responsiveness of mildly asthmatic patients [15].
Asthmatic subjects should maintain their pre-exist-
ing ‘controller’ medication and be equipped with
an adequate supply of ‘rescue’ medications in the
form of inhaled bronchodilators and oral steroids
with appropriate instructions on their use. Breathing
cold dry air through a face mask may help to hu-
midify and warm the air entering the upper airways
to BTPS-conditions and hence reduce broncho-
constriction and airway inflammation.
It is not uncommon in non-asthmatic subjects, as a
result of the increasing hypoxic drive, to develop
clinical signs of an emotional hyperventilation syn-
drome without bronchial obstruction and/or a vocal
cord dysfunction syndrome. It is possible to differ-
entiate these “asthma” patients often clinically with
the help of a stethoscope.
Pulmonary hypertension due to other lung diseases
HAPE is a consequence of hypoxic pulmonary
vasoconstriction (HPV) and may be associated with
other diseases that cause a significant reduction of
the pulmonary vascular bed [16]. These include in-
terstitial and vascular lung diseases (primary forms
of pulmonary hypertension and thromboembolic
pulmonary diseases). Patients with lung diseases as-
sociated with pre-existing pulmonary hypertension
(mean PAP > 25 mm Hg at rest) are advised against
high altitude travel. If travel at altitudes above 2,500
m is unavoidable, supplemental oxygen should be
administered in all patients who have pulmonary
hypertension at sea level. The non-hypoxic compo-
nent of pulmonary hypertension should be treated
according to the therapy necessary for the specific
lung disease under normobaric conditions. If the
patient has no pre-existing pharmacotherapy for
pulmonary hypertension they should be given as






air 2 L/min O
2
Number of ventricular premature beats
Lown`s classification 
of VPBs
Grade 0 : no VPBs
 I : < 30 VPBs / hour 
 II : > 30 VPBs / hour
 III : multiform VPBs
 A   multifocal VPBs
 B   bigeminus
 IV : repetitive VPBs
 A   pairs (couplets)
 B   runs >3 in sequence     
 V : early VPBs (R on T)
8 p.m. - 6 a.m. (n = 13)
FIGURE 4: REDUCTION OF VENTRICURALR PREMATURE
BEATS (VPBs) DURING 2 L/MIN O2 BREATHING AT NIGHT IN
13 COPD PATIENTS
The ECG recordings during the night when breathing 2 litres nasal
O2/min compared with the night breathing only air show a signif-
icant reduction of ventricular premature beats in all 13 COPD
patients and allow an additional risk evaluation (vis-à-vis Lown`s
classification) of the intended altitude exposure.
FIGURE 5: PNEUMOTHORAX MANAGEMENT FIT FOR HIGH
ALTITUDE TRANSPORT
Closed (non-ventilated) air spaces expand with increasing altitude
(= closed pneumothorax) and shrink during descent. Therefore
patients with pneumothorax need a chest tube with one way valve
which also prevents tension pneumothorax due to ambient pres-
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for the duration of the stay at altitude. Alternatives,
depending on the underlying lung disease, include
sildenafil, tadalafil and dexamethasone to reduce
the hypoxic increase of pulmonary hypertension
due to altitude exposure. The acute therapeutic re-
sponse of phosphodiesterase-5 inhibitors, cortico -
steroids, calcium channel blockers and other pul-
monary vasodilators (bosentan, iloprost) makes it
impossible to predict the long-term effect of these
drugs on pulmonary artery pressure either at sea
level or at altitude (16).
COPD
The situation in which patients with COPD are most
often exposed to altitude is when flying (Figure 6),
but some times they are also exposed as long-term
residents. An important issue for them is the pres-
ence of bullous lung disease. In contrast to decom-
pression in divers the expansion of these structures
during altitude exposure does not appear to be a
risk for pneumothorax. Increases of pulmonary ar-
tery pressure (pulmonary hypertension) are depend-
ent on the initial pressure at departure level, the
possibility of recruitment of the pulmonary vascular
bed and the availability of oxygen to compensate
the alveolar hypoxia induced vasoconstriction.
Since non-invasive pulmonary artery pressure meas-
urements with ECHO are not easy to perform in
COPD patients, spirometry is recommended. Patients
with FEV1 < 1,5 L should be assessed with pulsoxime-
try and an arterial CO2 measurement. These allow to
detect hypoxemia and hypercapnia today also non-in-
vasively. If supplemental O2-breathing (2-4 L/min)
does not lead to a sufficient O2 saturation of 94%
(equivalent to 70-75 mm Hg PaO2) at the altitude level
of assessment, the patient should not be recommend-
ed for hypoxic exposures above 2,500 m.
The same evaluation criteria can be applied to pa-
tients with cystic fibrosis [17]. 
Patients with hypercapnic ventilatory failure (global
respiratory insufficiency) at sea level are generally
not able to sustain the increased hypoxic drive at al-
titude without additional oxygen breathing. Often
they need also ventilatory support (non invasive
ventilation). An optimal antiobstructive inhalation
therapy with tiotropium bromide, indacaterol, topi-
cal steroids and possibly oral theophylline, which
has also a positive effect on AMS, should be estab-
lished [18]. 
Interstitial lung diseases (ILD)
ILD generally present with hypoxemia and normo-
FIGURE 6: MEAN PULMONARY ARTERY PRESSURE (PAP) ABOVE 30 MM HG EXCLUDES FROM FLYING WITHOUT O2 INCREASES
IN ALL 10 COPD PATIENTS EXPOSED TO A CABIN PRESSURE EQUIVALENT TO AN ALTITUDE OF 2,500 M ABOVE SEA LEVEL
All patients increased their mean PAP far more than normal subjects range. One patient had a pre-flight PAP of more than 30 mm Hg
(complete vascular recruitment) and could not tolerate the altitude exposure. Residual volume correlated best with PAP, all patients fell
asleep during the hypobaric exposure and showed a decrease in FEV1 from 1.08 to 0.78 L, the FEV1/IVC ratio diminishing from 45.7 to































6 or hypocapnia. If at rest and during exercise supple-
mental oxygen breathing restores normal arterial
pO2 values at sea level, these patients can travel to
moderate altitudes without problems as long as they
do not also suffer from pulmonary hypertension. In
contrast to obstructive lung diseases the response of
pulmonary artery pressures on O2-breathing is more
limited in patients with ILD than in those with
COPD (Figure 7). The restriction of the vascular bed
in ILD patients is generally less functional (alveolar
hypoventilation induced) but more structural.
Pulmonary vasodilators (nifedipine, sildenafil) oth-
FIGURE 7: DEPENDENCY OF MEAN PULMONARY ARTERY PRESSURE (PAP) RESPONSE ON O2-BREATHING AS A FUNCTION OF
RESIDUAL VOLUME (RV) AND AIRWAY RESISTANCE (RAW) % PREDICTED
TABLE I: LAKE LOUISE ACUTE MOUNTAIN SICKNESS SCORING SYSTEM
Self reported symptoms: (Score)
Headache: no (0), mild (1), moderate (2), severe, incapacitating (3)
Gastrointestinal: no (0), poor appetite or nausea (1), moderate nausea or 
nausea (2), severe nausea and vomiting, incapacitating (3)
Fatigue and/or weakness: no (0), mild (1), moderate (2), severe (3)
Dizziness or light headedness: no (0), mild (1), moderate (2), severe, incapacitating (3)
Difficulty to sleep: as well as usual (0), not as well as usual (1), poor night sleep,     
woke up many times (2), could not sleep at all (3)
Clinical assessment: (Score)
Change in mental status: no (0), lethargy or lassitude (1), disorientated or confused (2),
stupor or semi-consciousness (3), coma (4)
Ataxia (heel-to-toe walking): no (0), manoeuvres to maintain balance (1), steps off line (2),
falls down (3), cannot stand (4)
Peripheral edema: no (0), at one location (1), at two or more locations (2),
If you have any symptoms 
how do they affect your activity?: no reduction (0), mild (1), 
moderate (2),  severe  reduction, e.g bed rest (3)
The scoring system tries to quantify the severity of acute mountain sickness (AMS). A score (sum of the points) of 3 or more on the 
self-reported symptoms section, or for the combined self-reported questionnaire and clinical assessment of more than 3, while at 
altitude above 2,500 m, indicates AMS.
Responders








Non-responders 02 responders show an obstructive pattern
Legenda: open circles: baseline at; full circles: on oxygen.
A: The response of mean PAP on O2-breathing is lower in interstitial lung disease patients with low residual volume (RV% pred) and sub-
normal airway resistance (RAW %pred) compared to patients with increased airway resistance and over-inflation.
B: Chest x-ray of a typical patient with interstitial lung disease variations in PAP and blood gases between baseline conditions and when
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er than supplemental O2 have limited therapeutic
potential, but if it can be demonstrated in an acute
setting that one or a combination of these drugs
lowers pulmonary hypertension, they should be
administered especially for short altitude expo-
sures [19].
Pulmonary thromboembolic disease
Patients with known thromboembolic complica-
tions, including smoking females with underlying
coagulopathy and/or oral contraceptive use, are at
increased risk during long distance flights or bus
travel or other activities with a high degree of im-
mobility. Restricted leg movement, venous occlu-
sion (backpacking) and dehydration should be
avoided. Any anticoagulant therapy started at sea
level should be continued at altitude together with
all other drugs prescribed to reduce pulmonary hy-
pertension and disease-specific symptoms. There
are anecdotal reports that lung emboli after thoracic
surgery are less frequent if the operation is per-
formed above 1,800 m compared to in lowland
hospitals.
Respiratory pump disorders
Few studies have examined patients with respiratory
pump disorders. Patients needing non-invasive ven-
tilation (NIV) as a consequence of pump failure,
alone or in combination with lung diseases and res-
piratory muscle fatigue, are generally not fit for trav-
elling to altitudes above 2,500 m. They should also
avoid long distance flights without supplemental
O2-breathing and the support of a mechanical ven-
tilator.
Obesity hypoventilation
Patients with this syndrome are at risk of cor pul-
monale and hence acute right heart failure under an
additional hypoxic stress at altitude inducing more
pulmonary vasoconstriction. Nocturnal hypoxemia
(especially during REM sleep) due to obesity in-
duced hypoventilation predisposes to both AMS
and HAPE. Pulmonary artery pressures at altitude
increase in proportion to the body mass index (BMI
> 30 kg/m2, PaCO2 during the day > 45 mm Hg).
Patients without daytime pulmonary hypertension
who need only continuous positive airway pressure
(CPAP) or non-invasive ventilation (NIV) at night
can travel to moderate altitudes with their devices,
but should also get prophylactic drug therapy as
needed.
Obstructive and/or central sleep apnea
Patients with OSAS develop already subclinical
HAPE at moderate altitudes of 2,500-3,000 m [19].
Their symptoms of AMS benefit from 750 mg/d 
acetazolamide as well as fluid retention and sys-
temic blood pressure elevation. Pulmonary gas ex-
change improved during the verum compared to
the placebo night [20]. Patients with pulmonary hy-
pertension and/or day time hypoxemia at sea level
need slow release nifedipine 20 mg b.i.d. with sup-
plemental oxygen at night. 
Carotid surgery and control of breathing 
The hypoxemic ventilatory response is reduced in
patients who have undergone endarterectomy with
damage to the carotid body. These patients may
show no increase of ventilation under hypoxic
stress and therefore they have a high risk of devel-
oping AMS and HACE. If these patients need to travel
at altitude, they should be first tested for their hyper-
oxic ventilatory response, to verify if there is a sup-
plemental O2-induced hypoventilation.
Neuromuscular diseases and thoracic malforma-
tions
Patients with muscular dystrophies, diaphragmatic
paralysis, amyotrophic lateral sclerosis (ALS),
Guillain-Barré syndrome or severe kyphoscolioses
have limited ability to increase their ventilation as
required for altitude adaptation. Often they first 
hypoventilate during sleep at night and later during
day time at sea level and need non-invasive ventila-
tion (NIV) or bi-level positive airway pressure
(BiPAP). Any prior treatment with BiPAP or NIV
should be continued at altitude. Nocturnal or even
24 hour supplemental O2-breathing may be indicat-
ed to avoid at altitude an additional alveolar hypoxia-
induced pulmonary vasoconstriction. Patients with
kyphoscoliosis and pulmonary hypertension need
additional oxygen combined with slow release
nifedipine 20 mg b.i.d. In patients with bilateral di-
aphragmatic paralysis NIV is already indicated dur-
ing moderate altitude exposure.
CONCLUSION
In conclusion, what do we need to evaluate if a pa-
tient is fit for altitude exposure? In the first instance,
the patient’s clinical diagnosis, medical examina-
tion and history (former experience with altitude ex-
posures) are required. Specific examinations that
should be carried out are: pulsoximetry (Hb,
PaCO2), spirometry, chest X-ray, RR (echocardiogra-
phy). If one or more of these are abnormal, for alti-
tude exposures above 2,500 m further tests should
be carried out on air- versus O2-breathing: SaO2-,
PaCO2-, PAP-response under supplemental 
O2-breathing. If still abnormal, prophylactic drug
therapy is recommended: acetazolamide (250 mg
b.i.d.), dexamethasone (2 mg b.i.d.), sildenafil 
(20 mg b.i.d.) [11,23], nifedipine slow release (20
mg b.i.d.). In the case of ventilatory (respiratory
pump, periodic breathing) insufficiency with and
without lung and heart failure: polysomnography
should be performed in all patients, if necesssary
with and without supplemental O2-breathing and/or
mechanical aids at night (CPAP, BiPAP, IPPV, added
dead space) and drug therapy [9,12,20,22]. 
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